All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.
The Lymphoma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
An expert panel hosted by
Sequencing immune-based therapies in B-cell malignancies
with Ulric Jäger, Sagar Lonial, and Krina Patel
Saturday, June 15 | 18:00-19:30 CEST
Register nowThis independent education activity is sponsored by Bristol Myers Squibb. All content is developed independently by the faculty. Funders are allowed no direct influence on the content of this activity.
The Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
How do cell-of-origin and molecular features influence outcomes in R/R DLBCL?
Bookmark this article
During the 16th International Conference on Malignant Lymphoma (16-ICML), the Lymphoma Hub spoke with Sanjal Desai, Mayo Clinic, Rochester, US. We asked, How do cell-of-origin and molecular features influence outcomes in relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL)?
How do cell-of-origin and molecular features influence outcomes in R/R DLBCL?
Desai describes a retrospective study investigating cell-of-origin using gene expression profiles or immunohistochemistry, and the influence on prognosis in patients with R/R DLBCL. This includes double-hit lymphoma (MYC and BCL2 and/or BCL6 rearrangements) and double-expressor lymphoma (MYC and BCL2 overexpression).
Understanding your specialty helps us to deliver the most relevant and engaging content.
Please spare a moment to share yours.
Please select or type your specialty
Thank youRelated articles
Newsletter
Subscribe to get the best content related to lymphoma & CLL delivered to your inbox